Ever Supreme Bio Technology Co., Ltd.   Report issue

For profit Phase 1 Phase 2
Founded: Taichung Taiwan (2016)

Organization Overview

First Clinical Trial
2019
NCT04056819
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Ever-Supreme Biotechnology | Ever Supreme Bio Technology Co., Ltd.

Active Ingredients

Drugs in Phase 2 Trials (1)

autologous dendritic cells (1 trial)

Drugs in Phase 1 Trials (2)

umbilical cord mesenchymal stem cells (1 trial)

umsc01 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Glioblastoma (Phase 2)

Infarction (Phase 1)

Myocardial Infarction (Phase 1)

Stroke (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 3